Aged Clinical Trials as Topic Humans Lasers Semiconductor Male Postoperative Complications/etiology Postoperative Period Prostatic Hyperplasia Publication Bias Quality of Life Risk *Transurethral Resection of Prostate Treatment Outcome Bhp Diode laser Enucleation Meta-analysis Plasmakinetic

Blood Transfusion Clinical Trials as Topic Humans Length of Stay Male Minimally Invasive Surgical Procedures Operative Time Prostate Prostatectomy Prostatic Hyperplasia Quality of Life Treatment Outcome Urinary Retention *benign prostatic hyperplasia *laparoscopic *minimally invasive simple prostatectomy *open simple prostatectomy *robotic

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Animals Biological Availability Clinical Trials as Topic Flavonoids/pharmacology/*therapeutic use Flavonols/pharmacology/*therapeutic use Humans Inhibitory Concentration 50 Kaempferols/pharmacology/*therapeutic use Male Models Animal Prostatic Neoplasms/*drug therapy Urinary Bladder Neoplasms/*drug therapy bladder cancer fisetin kaempferol myricetin prostate cancer

Administration Intravesical Antineoplastic Agents/*administration & dosage/adverse effects Clinical Trials as Topic Disease Progression Humans Neoplasm Metastasis *Neoplasm Recurrence Local Network Meta-Analysis Progression-Free Survival Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*drug therapy/mortality/pathology

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/immunology/mortality/pathology/*therapy Chemotherapy Adjuvant/methods/statistics & numerical data Clinical Trials Phase I as Topic Clinical Trials Phase II as Topic Cystectomy Disease-Free Survival Follow-Up Studies Humans Immune Checkpoint Inhibitors/*therapeutic use Muscle Smooth/pathology/surgery Neoadjuvant Therapy/*methods/statistics & numerical data Neoplasm Invasiveness/pathology Prospective Studies Treatment Outcome Urinary Bladder/pathology/surgery Urinary Bladder Neoplasms/immunology/mortality/pathology/*therapy Bladder cancer Immune checkpoint inhibitors Immunotherapy Neoadjuvant

Antibodies Monoclonal/adverse effects/therapeutic use Antibodies Monoclonal Humanized/adverse effects/therapeutic use Antineoplastic Agents Immunological/*therapeutic use B7-H1 Antigen/*antagonists & inhibitors Clinical Trials Phase III as Topic Humans Network Meta-Analysis Programmed Cell Death 1 Receptor/*antagonists & inhibitors Salvage Therapy/*methods Survival Analysis Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/*secondary PD-1 inhibitor PDL-1 inhibitor atezolizumab pembrolizumab urothelial bladder cancer

Controlled Clinical Trials as Topic Cystectomy/*methods Female Humans Male *Quality of Life Reproducibility of Results Surveys and Questionnaires Treatment Outcome Urinary Bladder Neoplasms/pathology/psychology/*surgery Urinary Diversion/methods/*psychology *Urinary Reservoirs Continent Health related quality of life Ileal conduit Meta-analysis Orthotopic neobladder Radical cystectomy Urinary diversion

Adult Aged Aged 80 and over Antibodies Monoclonal/therapeutic use Antibodies Monoclonal Humanized/therapeutic use B7-H1 Antigen/*antagonists & inhibitors/genetics CTLA-4 Antigen/*antagonists & inhibitors/genetics Clinical Trials as Topic Female Genes cdc/drug effects Humans Ipilimumab Male Middle Aged Neoplasm Metastasis/*drug therapy/genetics/pathology Nivolumab Urinary Bladder Neoplasms/*drug therapy/genetics/pathology Bladder cancer immunotherapy Checkpoint inhibitor Pembrolizumab